Fused Heteroaryl Compounds for Selective Sodium Channel Modulation

The patent applies local quality by designing compounds with specific molecular structures (fused heteroaryl cores with particular substituent patterns) that selectively interact with abnormal sodium channel conformations associated with INaL, rather than affecting all sodium channel states uniformly. This structural specificity enables preferential binding to pathological channel states while sparing normal physiological function.

The patent employs parameter changes by systematically varying molecular parameters of the compound structure (such as heteroaryl ring types, substituent positions, and side chain configurations) to optimize selectivity for abnormal INaL. These structural parameter adjustments allow fine-tuning of the compound's interaction with sodium channels to achieve therapeutic selectivity.

The patent applies inversion by designing compounds that do not simply block sodium channels in a non-selective manner, but rather exploit the conformational differences between normal and abnormal channel states. The compounds are structured to preferentially bind to and stabilize abnormal channel conformations, effectively reversing the typical approach of broad-spectrum blockade.

The patent uses intermediary principles by introducing compounds that act as molecular mediators between the abnormal sodium channel conformation and the desired therapeutic effect. These fused heteroaryl compounds serve as intermediaries that specifically recognize and bind to pathological channel states, translating the conformational difference into selective pharmacological action.